The Inflation Reduction Act’s Medicare Drug Price Negotiation Program

The Inflation Reduction Act's Medicare Drug Price Negotiation Program

The Centers for Medicare & Medicaid Services (CMS) recently unveiled transcripts from a series of patient-focused listening sessions, a pivotal element of the Inflation Reduction Act’s Medicare Drug Price Negotiation Program.

These sessions, conducted between Oct. 30 and Nov. 15, 2023, marked a significant step forward in the Program’s mission to make prescription drugs more affordable for Medicare Part D enrollees. Specifically, these sessions focused on the inaugural set of 10 drugs selected for negotiation, which treat a range of medical conditions, including diabetes, blood clots, heart failure, psoriasis, rheumatoid arthritis, Crohn’s disease, and blood cancers.

The drugs in question – Farxiga, Fiasp/NovoLog, Januvia, Jardiance, Eliquis, Xarelto, Entresto, Stelara, Enbrel, and Imbruvica – were chosen for their clinical importance and the financial burden they impose on patients. These sessions provided a platform for patients, caregivers, and representatives from consumer and patient organizations to voice their experiences, concerns, and hopes regarding access to these critical medications under the new negotiation framework.

While much of the public discourse surrounding the Medicare Drug Price Negotiation Program has revolved around the technicalities of the negotiation process, potential impacts on drug development, and legal challenges from pharmaceutical companies, less attention has been paid to the Program’s implications for Medicare Part D enrollees’ access to and utilization of these medications.

Key provisions of the law are designed to ensure broad access to these medications once negotiated prices come into effect in 2026. All Medicare Part D plans will be required to cover each of the negotiated drugs in all available dosages and forms. Furthermore, CMS will closely monitor and regulate the placement of these drugs on formulary tiers, ensuring that any decision to place these drugs on non-preferred tiers, which typically involve higher cost-sharing for patients, is well-justified.

Additionally, CMS aims to curtail the use of utilization management tools like prior authorization requirements for these drugs, potentially easing administrative hurdles and facilitating easier access to these medications for enrollees. Despite the currently high coverage rates for most of these drugs across Part D plans, variations do exist, particularly in the coverage of different dosages and forms. For example, while nearly all enrollees have access to Xarelto tablets, coverage for its oral suspension drops to 78 percent. Similarly, coverage varies for different forms of Imbruvica, with a slight decrease in coverage for higher-dosage forms. As the Medicare Drug Price Negotiation Program moves forward, these measures reflect a comprehensive approach to not only lowering drug prices, but also ensuring that enrollees have the access they need to critical medications. This balanced focus on affordability and accessibility highlights the Program’s potential to significantly impact the lives of millions of Americans reliant on Medicare Part D for their prescription drug coverage.

Facebook
Twitter
LinkedIn

Timothy Powell, CPA, CHCP

Timothy Powell is a nationally recognized expert on regulatory matters, including the False Claims Act, Zone Program Integrity Contractor (ZPIC) audits, and U.S. Department of Health and Human Services (HHS) Office of Inspector General (OIG) compliance. He is a member of the RACmonitor editorial board and a national correspondent for Monitor Mondays.

Related Stories

Leave a Reply

Please log in to your account to comment on this article.

Featured Webcasts

Inpatient Ulcers and Gangrene: Avoid FY 2027 ICD-10-CM Coding, Sequencing, and Documentation Errors

Avoid costly inpatient coding errors involving ulcers and gangrene. This practical FY 2027 ICD-10-CM webcast clarifies pressure injury staging, non-pressure ulcer severity, diagnosis sequencing, documentation requirements, and POA reporting. Through real-world cases, gain the confidence to make defensible coding decisions, reduce denials, strengthen compliance, and support accurate reimbursement.

November 4, 2026

One Chart, Five Truths: How CDI Prevents the Same Diagnosis from Becoming Five Different Outcomes

What happens when everyone reviews the same chart, but reaches a different conclusion? In this case-based clinical documentation integrity (CDI) webcast, Penny Jefferson examines how documentation involving clinical support, timing, causation, linkage, and terminology can produce very different outcomes for ICD-10 coding, reimbursement, quality, risk adjustment, medical necessity, denials, and compliance. Using cases involving postoperative respiratory failure, severe malnutrition, and encephalopathy, you’ll learn the practical CLEAR framework to help attendees learn to evaluate whether a diagnosis is codeable, consistent, specific, reportable, and ultimately defensible across the different teams and systems that rely on the medical record.

September 30, 2026

Mastering Spinal Fusion Coding for Inpatient Facilities: ICD-10-PCS Precision, Documentation, and MS-DRG Impact

Spinal fusion cases are among the most complex inpatient procedures to code, where even minor ICD-10-PCS errors can affect MS-DRG assignment, reimbursement, compliance, and audit outcomes. This practical webcast provides a step-by-step framework for interpreting operative reports, assigning accurate ICD-10-PCS codes, recognizing documentation gaps, and confidently coding complex fusion procedures. You’ll leave with practical tools that improve coding accuracy, reduce denials and audit risk, and strengthen documentation-driven reimbursement decisions.

July 29, 2026

Trending News

Featured Webcasts

Radiation Oncology Fundamentals: Coding, Billing & Compliance for Hospital Outpatient & Professional Services

Now Available On Demand

Join Michael Calahan, PA, MBA for this radiation oncology coding and compliance webcast as he explains the fundamentals of coding, billing, reporting, and documentation for hospital outpatient and professional services. Learn how the 2026 radiation therapy coding changes affect current practices, how to distinguish technical and professional services, and how to address bundling, units, frequency, modifiers, and documentation requirements. Michael will also help you identify radiation oncology coding and billing vulnerabilities that could lead to denials, overpayments, repayment demands, or federal audit exposure.

October 20, 2026

Trending News

Prepare for the 2025 CMS IPPS Final Rule with ICD10monitor’s IPPSPalooza! Click HERE to learn more

Get 15% OFF on all educational webcasts at ICD10monitor with code JULYFOURTH24 until July 4, 2024—start learning today!

This Memorial Day, we honor those who gave all for our freedom. Take 20% off sitewide through May 29 with code MEMORIAL26 at checkout

CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 1 with code CYBER25

CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24